替尔泊肽(Tirzepatide) - 药物靶点：GIPR x GLP-1R_在研适应症：肥胖，超重，2型糖尿病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Tirzepatide (USAN)、DehydraTECH-替尔泊肽、替西帕肽

+ [8]

靶点

GIPR x GLP-1R

作用机制

GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病心血管疾病+ [4]

在研适应症

肥胖超重2型糖尿病+ [7]

非在研适应症

低血糖终末期肾脏病肝功能衰竭

原研机构

Lexaria Bioscience Corp.

Eli Lilly & Co.

在研机构

Eli Lilly Australia Pty Ltd.

美国礼来亚洲公司上海代表处

Eli Lilly & Co.

+ [5]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-05-13),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)

登录后查看首次获批时间轴

序列信息

Sequence Code 1273099312

来源: *****

关联

103

项与替尔泊肽相关的临床试验

NCT06534411 / Not yet recruiting临床3期

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

开始日期2024-11-05

申办/合作机构

Novo Nordisk A/S

NCT06162715 / Not yet recruiting临床2期IIT

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial

The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.

开始日期2024-10-01

申办/合作机构

Vanderbilt University Medical Center

NCT06518837 / Not yet recruiting临床2期IIT

FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).

开始日期2024-09-30

申办/合作机构

Rutgers State University of New Jersey

[+1]

100 项与替尔泊肽相关的临床结果

登录后查看更多信息

100 项与替尔泊肽相关的转化医学

登录后查看更多信息

100 项与替尔泊肽相关的专利（医药）

登录后查看更多信息

330

项与替尔泊肽相关的文献（医药）

2024-04-01·The Annals of pharmacotherapy

Incretin Analogs for Weight Management in Adults Without Diabetes

Review

作者: Lobkovich, Alison ; Lipari, Melissa ; Kale-Pradhan, Pramodini

Objective::

This is a narrative review of incretin analogs and their effect on weight management in adult without diabetes.

Data Sources::

Randomized controlled trials were identified by English language. PubMed/MEDLINE, Scopus, and Embase databases were searched from inception through June 2023 to identify all pertinent trials reporting outcomes on efficacy and safety search using the terms: tirzepatide, semaglutide, liraglutide, and obesity.

Study Selection and Data Extraction::

Selected studies were included if the study population was composed of adults without diabetes being treated by glucagon-like peptide 1 (GLP-1) receptor agonists or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists for weight management, and weight loss was assessed as a primary outcome.

Data Synthesis::

Fifteen studies involving 3 pharmacotherapies (liraglutide, semaglutide, and tirzepatide) were identified. Efficacy data supporting the use of these agents for weight management were promising when compared to placebo and/or other behavioral therapies. Percent weight loss ranged from 5.7% to 11.8%, 14.9% to 17.4%, and 15% to 20.9% for liraglutide, semaglutide, and tirzepatide, respectively. Safety data were relatively similar across all trials and identified gastrointestinal adverse effects as most common.

Relevance to Patient Care and Clinical Practice::

Glucagon-like peptide 1 agonists are preferred for overweight or obese patients by the American Gastroenterological Association. Future guidelines may address tirzepatides’ place in therapy as new evidence comes forth. Providers should consider patient-specific factors such as cost, adverse effects, drug interactions, and comorbidities when prescribing these agents and provide education regarding the need for concurrent diet and exercise modifications.

Conclusions::

All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.

2024-03-01·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

作者: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

2024-03-01·Diabetes, obesity & metabolism

A comment on tirzepatide versus glucagon‐like peptide‐1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis’

Review

作者: Goldenberg, Ronald M

2,061

项与替尔泊肽相关的新闻（医药）

2024-09-17

·BioSpace

GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study

iStock, KKStock In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis. GLP-1 receptor agonists appear to significantly reduce the risk of progression to cirrhosis—and its related complications—in patients with metabolic dysfunction-associated steatotic liver disease, according to a cohort study published Monday in JAMA Internal Medicine . Drawing from the U.S. Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry, the retrospective analysis looked at data from more than 16,000 patients who initiated treatment with GLP-1 receptor agonists. The study found that more than 14,600 patients did not have cirrhosis at baseline. Compared with patients who took DPP-4 inhibitors, GLP-1 treatments reduced the risk of progressing to cirrhosis by 14%, an effect that was statistically significant. GLP-1 receptor agonists were also associated with significantly lower risks of cirrhosis complications and mortality, reducing the respective likelihoods by 22% and 11%. If confirmed by clinical trials, the researchers contend that these findings point to the potential of GLP-1 receptor agonists as preventive treatments for cirrhosis and related complications in patients with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). By comparison, in the approximately 1,400 patients with cirrhosis at baseline, GLP-1 therapy did not significantly correlate with any of the target outcomes. This result underscores “the importance of treatment earlier in the disease course,” the researchers wrote. GLP-1 receptor agonists comprise a rapidly growing class of therapies that work by mimicking the structure of the GLP-1 hormone to target and activate its corresponding receptor. The therapies promote the secretion of insulin from the pancreas in response to blood sugar levels and slow down gastric emptying to help suppress appetite. Pharma companies have leveraged this mechanism of action to target the lucrative weight loss drug market. According to analysts, the obesity market could exceed $150 billion in the 2030s. Leading the pack are Novo Nordisk, which markets its semaglutide therapy as Ozempic for type 2 diabetes and Wegovy for obesity, and Eli Lilly, which sells tirzepatide as Mounjaro for type 2 diabetes and Zepbound for obesity. Further fueling the growth of GLP-1s is pharma’s continued efforts to push the drug class into new indications. In March 2024, Novo won the FDA’s approval to use Wegovy to lower the risk of cardiovascular death, heart attack and stroke in patients who are overweight or obese and who have cardiovascular disease. Lilly, meanwhile, is positioning Zepbound as a therapy for obstructive sleep apnea and an FDA decision could come as early as the end of 2024.

上市批准临床结果

2024-09-15

·医药观澜

礼来重磅新药「替尔泊肽」新适应症在中国申报上市

▎药明康德内容团队报道今日（9月15日），中国国家药监局药品审评中心（CDE）网站最新公示，礼来（Eli Lilly and Company）重磅药物GIP/GLP-1受体双重激动剂替尔泊肽注射液新适应症上市申请获得受理，具体适应症尚未披露。根据CDE官网查询，这是替尔泊肽在中国递交的第三项上市申请。根据该产品在国际范围内的注册进展以及中国临床研究进程，推测本次申报上市的适应症可能是改善中重度阻塞性睡眠呼吸暂停（OSA）肥胖患者的打呼情况。针对这一适应症，礼来已经向FDA递交了上市申请。此外，替尔泊肽针对合并肥胖的射血分数保留性心力衰竭适应症的国际多中心（含中国）3期临床研究也已经完成，并取得积极结果。截图来源：CDE官网替尔泊肽（tirzepatide）是一款葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂，每周一次注射。该产品分别于2022年5月和2023年11月获得FDA批准，用于糖尿病以及肥胖和超重患者。在中国，替尔泊肽于今年5月获批首个适应症，用于成人2型糖尿病患者血糖控制。今年7月，该产品再次获NMPA批准用于改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。目前，礼来也持续不断探索替尔泊肽在各种适应症上的应用。8月初，礼来宣布已经向欧洲和美国的监管机构递交申请，寻求批准替尔泊肽改善中重度阻塞性睡眠呼吸暂停（OSA）肥胖患者的打呼情况。礼来指出，这一适应症最快可能在今年年底之前获得FDA批准。SURMOUNT-OSA临床试验试验结果显示，与安慰剂相比，替尔泊肽平均减少患者呼吸暂停低通气指数（AHI）最高达62.8%，即每小时睡眠中减少约30次限制或阻塞气流的事件。在中国，替尔泊肽针对阻塞性睡眠呼吸暂停和肥胖适应证的国际多中心（含中国）临床研究也已经完成。今年8月初，礼来还公布替尔泊肽的国际多中心（含中国）临床3期试验（SUMMIT研究）达到积极顶线结果。分析显示，试验达成主要终点，与安慰剂相比，替尔泊肽注射液可将肥胖射血分数保留型心力衰竭（HFpEF）患者发生心衰相关事件的风险降低38%。礼来表示计划从今年晚些时候开始向美国FDA和其他监管机构提交SUMMIT研究的结果。值得一提的是，SUMMIT试验在中国的部分也已经完成，中国入组了55名受试者。根据药物临床试验登记与信息公示平台官网，替尔泊肽还有多项3期临床研究已经在中国开展，针对适应症包括：用于成人超重和肥胖患者的药物干预治疗，降低其主要心血管事件的风险，减少2型糖尿病发生风险和改善肾脏结局；降低二型糖尿病伴心血管疾病风险增加的患者的主要不良心血管事件（MACE）的复合结局等。希望这款创新疗法尽快来到更多患者身边，为他们带来新的治疗选择。参考资料： [1] 中国国家药监局药品审评中心（CDE）网站.Retrieved Feb 15，2023, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]礼来官网. From https://www.lilly.com/innovation/clinical-development-pipeline 本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期临床结果临床成功申请上市

2024-09-14

·药智网

诺和诺德的新锚点

2024上半年，诺和诺德实现营收1334亿丹麦克朗，同比增长24%，业绩保持增长。司美格鲁肽的放量是业绩增长的关键因素。司美格鲁肽降糖注射剂Ozempic实现营收567亿丹麦克朗，司美格鲁肽降糖口服剂Rybelsus营收109亿丹麦克朗，司美格鲁肽减重注射剂Wegovy营收210亿丹麦克朗，司美格鲁肽合计销售额887亿丹麦克朗，同比增长43%，占诺和诺德总营收的2/3。在司美格鲁肽全球热卖的同时，诺和诺德也正在不断调整优化自身的研发策略和业务布局，通过丰富产品组合，进一步加强降糖减脂领域的霸主地位，同时，也在逐渐延伸慢病治疗边界。关注新生力量根据诺和诺德2024年中报显示，诺和诺德在企业战略发展方面，将糖尿病和肥胖业务作为关键优先研发领域，主要的战略举措则是进一步丰富相关治疗领域的产品组合，布局将更加广泛和深入。在减重领域，凭借Wegovy打开了肥胖症的市场。未来，诺和诺德将通过重点建立差异化的产品组合，从单纯的减重拓展到针对肥胖症患者的健康状况管理。除Wegovy外，复方制剂CagriSema已启动全球III期临床试验，两款全新的减重药物GLP-1R/胰淀素受体双靶点激动剂Amycretin、口服小分子CB1R反向激动剂Monlunabant的减重疗效也备受期待。 CagriSema是一款复方制剂，它包含2.4mg长效胰淀素受体类似物卡格列肽（Cagrilintide）和2.4mg长效GLP-1RA司美格鲁肽。CagriSema的II期临床数据显示，在治疗的32周，CagriSema治疗组体重下降15.6%，减重效果优于单独使用卡格列肽和司美格鲁肽。53.6%的CagriSema组受试者体重降幅超过15%。目前，CagriSema已启动全球III期临床，主要针对超重/肥胖症适应症。另外，针对伴有超重/肥胖的2型糖尿病适应症的全球III期临床、伴有心血管疾病的肥胖人群的全球III期临床也正在进行。诺和诺德Amycretin共开发了口服和皮下注射两种剂型。诺和诺德在今年的CMD会议上公布了口服Amycretin的初步I期临床数据：接受每日口服1次Amycretin治疗的患者，在治疗的第12周，体重较基线下降13.1%，对比安慰剂组受试者的体重降幅仅1.1%。目前，口服Amycretin已完成I期临床试验，皮下注射剂型Amycretin的I期临床试验数据预计将在2025年读出。另一款新药Monlunabant（INV-202）是一种CB1反向激动剂，CB1是一种大麻素受体，在调节食欲和心脏代谢中发挥重要作用。2023年8月，诺和诺德以10.57亿美元收购加拿大公司Inversago Pharma，由此，诺和诺德获得该公司的主要资产Monlunabant。 Monlunabant的I期临床数据显示，在治疗的第28天，Monlunabant组平均体重下降3.3%（即3.5KG），安慰剂组体重增长0.5%（即0.6KG）。Monlunabant治疗肥胖症和糖尿病肾病的II期临床试验正在进行。在降糖领域，目前诺和诺德的产品组合已覆盖胰岛素、注射型和口服型GLP-1药物。未来，诺和诺德将通过持续推进在研管线，将糖尿病的创新疗法扩展至糖尿病共患病中，例如糖尿病肾病等，以解决糖尿病管理中的尚未满足需求。延伸慢病治疗边界借助GLP-1产品的开发，诺和诺德的研发布局正在不断拓宽边界，朝着更广阔的慢病领域进发。根据券商研究资料显示，截至2023年底，司美格鲁肽全球共涉及148项临床试验，除了糖尿病和肥胖症适应症以外，在NASH、疼痛、慢性肾病、卒中等方面均有布局。其中，司美格鲁肽治疗NASH的Ⅱ期临床试验已取得积极疗效数据，目前正在进行全球III期临床试验。另外，司美格鲁肽在治疗射血分数保留型心力衰竭肥胖成人患者的III期临床试验中同样取得了积极的疗效结果。值得一提的是，GLP-1的另一巨头礼来，同样在扩展替尔泊肽的应用领域。根据礼来2024年中报资料，礼来已向FDA和EMA提交替尔泊肽用于治疗中度至重度阻塞性睡眠呼吸暂停的上市申请，预计FDA方面最早于2024年底给出相关回复。此外，礼来正在就替尔泊肽用于治疗代谢功能障碍相关的脂肪性肝炎的III期临床试验注册策略与有关监管机构进行洽谈。进军更广阔的心血管领域相较于其他跨国药企通过积极投资并购拓展业务领域，诺和诺德的并购活动则更为谨慎。2010年—2023年，诺和诺德仅进行过14项并购，在研发出GLP-1减重，心衰等适应症前，糖尿病是诺和诺德的核心，研发管线的高度专注是诺和诺德谨慎并购的核心原因。但是，自2020年开始，诺和诺德的并购步伐不断加快。尤其是2023年，6月-10月期间相继宣布5项并购项目，交易金额合计高达35亿美元。其中，收购Inversago Pharma公司和Embark Biotech是为了进一步强化肥胖领域的布局，在加码减重领域外，KBP Biosciences（2023）、Prothena（2021）、Corvidia Therapeutics（2020）的三项并购则强化了心血管疾病领域的研发能力。 2023年10月，诺和诺德以13亿美元从KBP Biosciences公司获得用于治疗心血管和肾脏疾病的高血压控制药物Ocedurenone，以加强自身心血管领域布局。Ocedurenone是一款口服小分子非甾体盐皮质激素受体拮抗剂，目前，正在开展用于治疗未得到控制的高血压合并晚期慢性肾病的III期临床试验，预计将在2024年9月完成。此前，Ocedurenone的Ⅱ期临床试验数据显示，在12周随机试验中，Ocedurenone能够使受试者的收缩压明显下降。此外，Ocedurenone的安全性高，高钾血症风险低于1%，并且无类固醇副作用。 2021年，诺和诺德以12亿美元收购Prothena公司，获得抗淀粉样蛋白免疫药物PRX004及其转甲状腺素蛋白淀粉样变性（ATTR）项目，目前ATTR项目正处于临床II期临床试验中。 2020年，诺和诺德以最高21亿美元收购Corvidia Therapeutics公司，获得IL-6单抗Ziltivekimab，通过阻断IL-6通路降低炎症，从而降低ASCVD和CKD患者的主要心血管不良事件风险，目前正在开展III期临床试验。这些正在孕育中的产品管线，如同未来业绩增长的“蓄水池”，随着日后的逐一兑现，还将为诺和诺德源源不断地贡献营收，成为新的重要增长点。核心产品放量增长，内生+外延并举，持续迎来研发进展，诺和诺德未来可期。参考资料： 1.诺和诺德历年业绩报告 2.诺和诺德2023年ADA会议报告 3.诺和诺德2024年资本市场日报告 4.礼来2024年中报 5.《从并购看诺和诺德业务布局思路》，华创证券声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史密斯转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

临床3期财报临床2期并购

100 项与替尔泊肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11360	替尔泊肽	-	DB15171

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Eli Lilly & Co.	2023-11-08
超重	美国	Eli Lilly & Co.	2023-11-08
2型糖尿病	美国	Eli Lilly & Co.	2022-05-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖通气不足综合征	申请上市	中国	Eli Lilly & Co.	2024-09-15
阻塞性睡眠呼吸暂停综合征	申请上市	美国	Eli Lilly & Co.	2024-06-21
体重增加	临床3期	美国	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	阿根廷	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	澳大利亚	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	加拿大	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	法国	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	德国	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	以色列	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	墨西哥	Eli Lilly & Co.	2024-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04184622 (SURMOUNT-1, Company_Website) 人工标引	临床3期	糖尿病前期 \| 超重 \| 肥胖	1,032	Tirzepatide 5 mg	餘蓋襯窪艱襯醖選繭衊(鹹構顧選夢艱蓋淵窪簾) = 廠繭範餘簾艱鏇夢齋網齋醖願壓範艱繭艱衊簾 (蓋鹽憲醖襯繭鏇積觸廠 )	积极	2024-08-20
				Tirzepatide 10 mg	餘蓋襯窪艱襯醖選繭衊(鹹構顧選夢艱蓋淵窪簾) = 鬱構網窪鏇鏇網繭憲鏇齋醖願壓範艱繭艱衊簾 (蓋鹽憲醖襯繭鏇積觸廠 )
NCT04847557 (SUMMIT, Company_Website) 人工标引	临床3期	射血分数保留型心力衰竭 \| 肥胖	731	Tirzepatide	艱艱網鹽憲窪築憲選築(蓋願遞糧鬱鬱積壓壓製) = 餘鬱獵網獵蓋憲艱鹽鑰蓋醖襯鏇糧蓋窪憲齋鑰 (艱選鹹選醖遞憲願網蓋 ) 更多	积极	2024-08-01
				Placebo	繭鏇繭膚廠醖網鬱襯憲(窪繭願製鏇簾範網艱壓) = 衊繭願艱鹹鏇願簾繭遞憲顧積築衊鹽蓋淵醖顧 (餘築顧餘願憲鬱鏇鹽襯 ) 更多
NCT04844918 (SURMOUNT-J, CTgov)	临床3期	肥胖	267	Tirzepatide (15 mg Tirzepatide)	製簾簾衊窪簾選鏇淵製(蓋製衊糧窪觸壓齋餘壓) = 網鹹鹹鏇鑰範構襯窪齋蓋鬱製繭鹹構齋繭顧製 (壓壓夢範鏇網積襯簾繭, 積膚製製範襯簾衊壓艱 ~ 淵艱積鹹醖淵醖築醖蓋) 更多	-	2024-07-16
				Placebo (Placebo)	製簾簾衊窪簾選鏇淵製(蓋製衊糧窪觸壓齋餘壓) = 製鏇餘糧衊鹽鏇鑰壓構蓋鬱製繭鹹構齋繭顧製 (壓壓夢範鏇網積襯簾繭, 夢憲鏇鏇廠艱築鏇醖製 ~ 廠構餘範築糧鬱糧繭網) 更多
NCT04657003 (SURMOUNT-2, ADA2024) 人工标引	临床3期	2型糖尿病 \| 肥胖	-	Tirzepatide	構醖襯廠鏇網網觸齋齋(鏇衊簾淵鬱襯淵蓋窪膚) = 積夢窪網簾蓋鬱襯遞積憲築膚製淵範選壓遞醖 (廠網網憲範觸壓網廠廠 )	积极	2024-06-21
				Placebo	-
NCT05412004 (SURMOUNT-OSA, Pubmed)	临床3期	阻塞性睡眠呼吸暂停综合征	-	Tirzepatide 10 mg	構齋鏇艱夢積鬱觸築醖(鑰醖獵鏇繭鑰築窪鹽廠) = 齋選簾膚選襯醖選願壓襯鏇鹹獵獵齋壓觸範選 (觸窪餘構窪願範膚選製, -29.3 ~ -21.2)	积极	2024-06-21
				Tirzepatide 15 mg	構齋鏇艱夢積鬱觸築醖(鑰醖獵鏇繭鑰築窪鹽廠) = 網憲齋觸積構醖鹽遞齋襯鏇鹹獵獵齋壓觸範選 (觸窪餘構窪願範膚選製, -33.2 ~ -25.4)
NCT04166773 (SYNERGY-NASH, Pubmed)	临床2期	MASH	190	Tirzepatide 5 mg	憲觸顧製鑰蓋遞遞窪膚(積鏇鑰糧鏇齋餘選簾艱) = 製範鹽範艱鑰積築簾願齋夢鹹蓋範齋製齋範顧 (積糧廠衊獵遞鹹鏇壓鹽, 17 ~ 50)	积极	2024-06-08
				Tirzepatide 10 mg	憲觸顧製鑰蓋遞遞窪膚(積鏇鑰糧鏇齋餘選簾艱) = 淵夢積鹽衊製齋網積蓋齋夢鹹蓋範齋製齋範顧 (積糧廠衊獵遞鹹鏇壓鹽, 29 ~ 62)
NCT04166773 (SYNERGY-NASH, Biospace \| EASL2024) 人工标引	临床2期	MASH	157	Tirzepatide 5mg	獵餘膚鏇鑰顧觸壓鬱窪(醖觸糧繭鹽夢壓願鬱蓋) = 鹽製製鹽醖選積衊觸餘鹹衊築膚願範壓製齋獵 (襯遞鑰願網壓餘夢築醖 ) 更多	积极	2024-06-05
				Tirzepatide 10mg	獵餘膚鏇鑰顧觸壓鬱窪(醖觸糧繭鹽夢壓願鬱蓋) = 網糧窪積鏇網襯積夢遞鹹衊築膚願範壓製齋獵 (襯遞鑰願網壓餘夢築醖 ) 更多
NCT02648204 \| NCT03987919 (SUSTAIN7, Pubmed) 人工标引	N/A	2型糖尿病二线	-	Tirzepatide 5mg	齋餘鹹遞膚鹹觸網壓窪(網製蓋淵簾鏇製顧淵糧) = Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol) and weight loss targets of ≥ 5 % and ≥ 10 %, versus semaglutide 0.5 mg. 壓鏇糧艱鑰齋繭鏇鏇選 (壓顧鏇窪網遞憲齋壓淵 )	积极	2024-06-01
				Tirzepatide 10mg
NCT05024032 (SURMOUNT-CN, Pubmed)	临床3期	肥胖 BMI	210	Tirzepatide 10 mg	顧範選鹽憲顧鏇淵餘憲(簾選鹹觸衊衊鹹選憲築) = 積簾鑰淵憲獵窪遞襯蓋鹹網醖淵顧觸觸鏇鏇簾 (築衊膚襯鑰夢醖鹽鏇鑰, -15.8% ~ -11.4%)	积极	2024-05-31
				Tirzepatide 15 mg	顧範選鹽憲顧鏇淵餘憲(簾選鹹觸衊衊鹹選憲築) = 網壓膚鏇餘簾鏇鏇衊遞鹹網醖淵顧觸觸鏇鏇簾 (築衊膚襯鑰夢醖鹽鏇鑰, -19.7% ~ -15.3%)
NCT04660643 (SURMOUNT-4, CTgov)	临床3期	2型糖尿病 \| 肥胖	783	Placebo (Placebo)	範鑰選構積簾衊齋淵範(壓齋積糧構繭簾遞夢網) = 蓋醖選膚顧衊積憲鹹衊鑰鏇網鬱膚餘構壓鏇鹽 (網構繭觸窪夢衊淵憲鏇, 獵鹹衊糧憲顧襯餘範蓋 ~ 網餘鏇憲積襯簾醖衊衊) 更多	-	2024-05-22
				Tirzepatide (Tirzepatide MTD)	範鑰選構積簾衊齋淵範(壓齋積糧構繭簾遞夢網) = 艱夢獵鹽糧構鏇鹽構築鑰鏇網鬱膚餘構壓鏇鹽 (網構繭觸窪夢衊淵憲鏇, 範糧獵網壓選艱廠淵糧 ~ 糧積鑰夢齋衊網艱觸壓) 更多